Madras Diabetes Research Foundation Signs MOU with CBR & UK DRI for Pioneering Diabetes and Brain Health Research
25th October 2025 | Chennai, India – In a significant international partnership, the Madras Diabetes Research Foundation (MDRF), Chennai, the Centre for Brain Research (CBR) at the Indian Institute of Science (IISc), Bengaluru, and the UK Dementia Research Institute (UK DRI) have come together to advance pioneering research into the complex links between diabetes and brain health. Separate Memoranda of Understanding (MoUs) were signed between MDRF, CBR, and UK DRI to formalize this collaboration.
Bringing together global leaders in diabetes, neuroscience, and dementia research, the initiative will explore how metabolic disorders such as diabetes contribute to cognitive decline and neurological diseases, including dementia and Alzheimer’s disease. The partnership aims to foster large-scale studies, data sharing, and translational research to improve early detection and preventive strategies.
Press meet Youtube Video link ЁЯСЗ
Dr. V. Mohan, Chairman, MDRF, said, “This partnership marks an important milestone in understanding how diabetes impacts not only the body but also the brain. By combining our strengths in metabolic research with global expertise in neuroscience, we aim to uncover mechanisms that can improve lives worldwide.”
Dr. R. M. Anjana, President, MDRF, noted, “With diabetes increasingly recognized as a risk factor for cognitive decline, this collaboration will help identify early markers of brain aging and open new avenues for prevention and therapy.”
Prof. Siddharthan Chandran, Director & Chief Executive, UK DRI, added, “Understanding how metabolic disorders affect brain function is one of today’s great scientific challenges. Collaborations like this accelerate discovery and translation into real-world benefits.”
Prof. K. V. S. Hari, Director, CBR, IISc, said, “Our work on brain aging and neurodegenerative diseases aligns closely with this effort. Partnering with MDRF and UK DRI enables the integration of large-scale clinical, imaging, and genomics data to unravel key biological pathways.”
Prof. Henrik Zetterberg, Head, Department of Psychiatry and Neurochemistry, University of Gothenburg, and Group Leader, UK DRI at UCL, remarked, “This collaboration opens exciting possibilities for dementia research. By studying metabolic and brain biomarkers together, we can uncover new insights into disease mechanisms and intervention strategies.”
****
